Why Johnson & Johnson Stock Still Has Room To Run

Summary

• On July 16, Johnson & Johnson did what I've been waiting for, namely, its revenue and EPS beat Wall Street analysts' expectations by a wide margin.
• The 42.7% year-over-year decline in sales of its "outdated" superstar Stelara was more than offset by the strong performance of its oncology franchise.
• Sales of Erleada, which is becoming the "gold standard" in prostate cancer treatment, reached $908 million, up 17.8% quarter-over-quarter.
• On July 29, 2025, Johnson & Johnson filed an sBLA to the FDA to add data showing that Tremfya slows joint damage in people with psoriatic arthritis.
• I believe Johnson & Johnson's stock still has room to rise.

Nastasic/E+ via Getty Images

Since my last article, "Johnson & Johnson Just Proved The Bears Wrong Again," Johnson & Johnson's stock price (NYSE:JNJ) has risen 8.5%.

But in my view, that number is less important than how the stock has responded to the growing fears

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.